直接抗病毒药物对肝移植的影响:对适应证演变与结果的重大影响——基于ELTR注册数据的ELITA研究
基于欧洲肝移植注册库(ELTR)的队列研究,分析2007年1月至2017年6月成人肝移植数据,按干扰素(IFN/RBV,2007-2010)、蛋白酶抑制剂(PI,2011-2013)和第二代直接抗病毒药物(DAA,2014-2017年6月)分期。DAA时代丙型肝炎(HCV)相关肝移植比例显著下降,HCV合并失代偿期肝硬化(HCV-DC)下降58.0%,HCV合并肝细胞癌(HCV-HCC)下降41.2%;HCV相关肝病移植受者3年生存率从IFN/RBV时代的65.1%提高至DAA时代的76.9%,与乙型肝炎病毒(HBV)感染受者相当(p=0.3807)。
要点
- DAA时代HCV相关肝移植比例从IFN/RBV时代的22.8%降至17.4%,NASH相关肝移植比例显著增加(p<0.0001)。
- DAA时代HCV相关肝移植比例从2014年上半年21.1%降至2017年上半年10.6%(p<0.0001)。
- HCV相关肝病移植受者3年生存率从IFN/RBV时代的65.1%提高至DAA时代的76.9%,与HBV感染受者相当(p=0.3807)。
核心结论
- 在欧洲,因HCV感染导致的肝移植数量在HCV-DC和HCV-HCC适应证上均快速下降,且肝移植后生存率在过去三年大幅改善。
- 这是首个全面研究HCV的DAA治疗对欧洲肝移植整体影响的研究。
研究设计与样本
- 基于欧洲肝移植注册库(ELTR)的队列研究,分析2007年1月至2017年6月间成人肝移植数据,包括HCV、HBV、酒精(EtOH)和非酒精性脂肪性肝炎(NASH)患者。
- 研究时期分为干扰素(IFN/RBV;2007-2010)、蛋白酶抑制剂(PI;2011-2013)和第二代直接抗病毒药物(DAA;2014-2017年6月)三个时代。
主要发现
- 在总共60,527例肝移植中,36,382例为HCV、HBV、EtOH和NASH患者。
- HCV相关肝病肝移植比例随时间显著变化(p<0.0001),从IFN/RBV时代的22.8%降至DAA时代的17.4%,而NASH相关肝移植比例显著增加(p<0.0001)。
- DAA时代HCV相关肝移植比例从2014年上半年的21.1%显著降至2017年上半年的10.6%(p<0.0001)。
- 该下降在失代偿期肝硬化患者(HCV-DC,-58.0%)中比在HCV相关肝细胞癌患者(HCV-HCC,-41.2%)中更明显。
- HCV相关肝病移植受者3年生存率从IFN/RBV时代的65.1%提高至DAA时代的76.9%,与HBV感染受者生存率相当(p=0.3807)。
临床怎么用
- HCV相关肝移植适应证的减少意味着有更多肝脏可供分配,每年至少600例可分配给非HCV适应证的惠者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Direct-acting antivirals (DAAs) have dramatically improved the outcome of patients with hepatitis C virus (HCV) infection including those with decompensated cirrhosis (DC). We analyzed the evolution of indications and results of liver transplantation (LT) in the past 10 years in Europe, focusing on the changes induced by the advent of DAAs. METHODS: This is a cohort study based on data from the European Liver Transplant Registry (ELTR). Data of adult LTs performed between January 2007 to June 2017 for HCV, hepatitis B virus (HBV), alcohol (EtOH) and non-alcoholic steatohepatitis (NASH) were analyzed. The period was divided into different eras: interferon (IFN/RBV; 2007-2010), protease inhibitor (PI; 2011-2013) and second generation DAA (DAA; 2014-June 2017). RESULTS: Out of a total number of 60,527 LTs, 36,382 were performed in patients with HCV, HBV, EtOH and NASH. The percentage of LTs due to HCV-related liver disease varied significantly over time (p <0.0001), decreasing from 22.8% in the IFN/RBV era to 17.4% in the DAA era, while those performed for NASH increased significantly (p <0.0001). In the DAA era, the percentage of LTs for HCV decreased significantly (p <0.0001) from 21.1% (first semester 2014) to 10.6% (first semester 2017). This decline was more evident in patients with DC (HCV-DC, -58.0%) than in those with hepatocellular carcinoma (HCC) associated with HCV (HCV-HCC, -41.2%). Conversely, three-year survival of LT recipients with HCV-related liver disease improved from 65.1% in the IFN/RBV era to 76.9% in the DAA era, and is now comparable to the survival of recipients with HBV infection (p = 0.3807). CONCLUSIONS: In Europe, the number of LTs due to HCV infection is rapidly declining for both HCV-DC and HCV-HCC indications and post-LT survival has dramatically improved over the last three years. This is the first comprehensive study of the overall impact of DAA treatment for HCV on liver transplantation in Europe. LAY SUMMARY: After the advent of direct-acting antivirals in 2014, a dramatic decline was observed in the number of liver transplants performed both in patients with decompensated cirrhosis due to hepatitis C virus (HCV), minus 60%, and in those with hepatocellular carcinoma associated with HCV, minus 41%. Furthermore, this is the first large-scale study demonstrating that the survival of liver transplant recipients with HCV-related liver disease has dramatically improved over the last three years and is now comparable to the survival of recipients with hepatitis B virus infection. The reduction in HCV-related indications for LT means that there is a greater availability of livers, at least 600 every year, which can be allocated to patients with indications other than HCV.
引用
- Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018. PMID: 29940268. doi:10.1016/j.jhep.2018.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。